Brian Ruffell

TL;DR: Blockade of pathways mediating macrophage recruitment, in combination with chemotherapy, significantly decreases primary tumor progression, reduces metastasis, and improves survival by CD8+ T-cell-dependent mechanisms, thus indicating that the immune microenvironment of tumors can be reprogrammed to instead foster antitumor immunity and improve response to cytotoxic therapy.

TL;DR: How macrophage shape local immune responses in the tumour microenvironment to both suppress and promote immunity to tumours is described and the potential of targeting tumour-associated macrophages to enhance antitumour immune responses is discussed.

TL;DR: This review discusses the molecular/cellular pathways identified so far whereby macrophages mediate therapeutic responses and therapeutics impacting macrophage presence and/or bioactivity have shown promise in preclinical models and are now being evaluated in the clinic.

TL;DR: Targeting molecular pathways regulating TAM polarization holds great promise for anticancer therapy.

TL;DR: Interleukin (IL)-10 expression by macrophages is identified as the critical mediator of this phenotype and expression of IL12A and cytotoxic effector molecules were predictive of pathological complete response rates to paclitaxel in human breast cancer.